Abstract
The anti-estrogen tamoxifen was the gold-standard adjuvant therapy for hormone-receptor-positive (HR+) early breast cancer for several decades, but has recently been displaced by the third-generation aromatase inhibitors (AIs). Three AIs are commercially available: letrozole, anastrozole and exemestane. All are more effective and at least as well tolerated as tamoxifen as adjuvant therapy for HR+ breast cancer in postmenopausal women. Despite the wealth of data comparing AIs with tamoxifen, it is unclear whether the three AIs are clinically equivalent, owing to the lack of head-to-head trials directly comparing them. Preclinical and small clinical studies suggest that letrozole is the most potent inhibitor of aromatase, reducing circulating estrogen levels to a greater degree than the other agents. However, whether this greater activity translates into superior clinical efficacy remains to be determined. In the absence of direct comparative data, cross-trial comparisons have been used to gain insights into any safety or efficacy differences. All three AIs have been compared directly with tamoxifen, and efficacy relative to tamoxifen has been compared across trials, although such analyses are complicated by differences in treatment schedules, patient populations and trial designs. Definitive conclusions cannot yet be drawn, but some important differences are coming to light, with upfront letrozole appearing particularly effective at preventing early distant metastasis, an event strongly associated with breast-cancer-related death. No safety differences between the AIs have yet been identified. This article explores the pharmacologic and clinical differences between the AIs, based on data from clinical and preclinical studies.
Similar content being viewed by others
References
Coates AS, Keshaviah A, Thurlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492. doi:10.1200/JCO.2006.08.8617
Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (intergroup exemestane study): a randomised controlled trial. Lancet 369:559–570. doi:10.1016/S0140-6736(07)60200-1
Howell A, Cuzick J, Baum M et al (2005) Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 365:60–62. doi:10.1016/S0140-6736(05)74803-0
Miller WR (1999) Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr Relat Cancer 6:187–195. doi:10.1677/erc.0.0060187
Geisler J, Haynes B, Anker G et al (2002) Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751–757. doi:10.1200/JCO.20.3.751
Geisler J, Ekse D, Helle H, Eystein-Lonning P (2006) Letrozole suppresses tissue and plasma estradiol, estrone and estrone sulfate more effectively compared to anastrozole. Breast Cancer Res Treat 100(suppl 1) (Abstract 103)
Dixon JM, Renshaw L, Young O et al (2006) Anastrozole and letrozole an investigation and comparison of quality of life, tolerability and morbidity. Breast Cancer Res Treat 100(suppl 1) (Abstract 105)
Eiermann W, Paepke S, Appfelstaedt J et al (2001) Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12:1527–1532. doi:10.1023/A:1013128213451
Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816
Smith IE, Dowsett M, Ebbs SR et al (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116. doi:10.1200/JCO.2005.04.005
Cataliotti L, Buzdar AU, Noguchi S et al (2006) Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative “Arimidex” compared to tamoxifen (PROACT) trial. Cancer 106:2095–2103. doi:10.1002/cncr.21872
Semiglazov V, Kletsel A, Semiglazov V et al (2005) Exemestane vs tamoxifen as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1–2, T3N01, T4N0M0). J Clin Oncol 23(suppl 16):11s (Abstract 530)
Mouridsen H, Gershanovich M, Sun Y et al (2001) Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596–2606
Bonneterre J, Buzdar A, Nabholtz JM et al (2001) Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 92:2247–2258. doi :10.1002/1097-0142(20011101)92:9<2247::AID-CNCR1570>3.0.CO;2-Y
Bonneterre J, Thürlimann B, Robertson JFR et al (2000) Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the tamoxifen or Arimidex randomized group efficacy and tolerability study. J Clin Oncol 18:3748–3757
Nabholtz JM, Buzdar A, Pollak M et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 18:3758–3767
Paridaens R, Therasse P, Dirix L et al (2004) First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)—a randomized phase III trial of the EORTC breast Group. J Clin Oncol 22:14S (Abstract 515)
Rose C, Vtoraya O, Pluzanska A et al (2003) An open randomised trial of second-line endocrine therapy in advanced breast cancer. Comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 39:2318–2327. doi:10.1016/S0959-8049(03)00630-0
Thürlimann B, Keshaviah A, Coates AS et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757. doi:10.1056/NEJMoa052258
Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139. doi:10.1016/S0140-6736(02)09088-8
Baum M, Buzdar A, Cuzick J et al (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98:1802–1810. doi:10.1002/cncr.11745
Trialists Group ATAC, Forbes JF, Cuzick J et al (2007) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53. doi:10.1016/S1470-2045(07)70385-6
Ries LAG, Melbert D, Krapcho M et al (2006) SEER cancer statistics review, 1975–2004. National Cancer Institute, Bethesda, MD. Available via: http://seer.cancer.gov/csr/1975_2004
Mansell J, Monypenny IJ, Skene AI et al (2006) Predictors of early recurrence in postmenopausal women with operable breast cancer. Breast Cancer Res Treat 3:100 (Abstract 2091)
Lamerato L, Havstad S, Gandhi S et al (2005) Breast cancer recurrence and related mortality in US patients with early breast cancer. J Clin Oncol 23:62s (Abstract 738)
Schairer C, Mink PJ, Carroll L, Devesa SS (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. J Natl Cancer Inst 96:1311–1321
Mauriac L, Keshaviah A, Debled M et al (2007) Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18:859–867. doi:10.1093/annonc/mdm001
Houghton J on behalf of the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) Trialists’ Group (2006) Initial adjuvant therapy with anastrozole (A) reduces rates of early breast cancer recurrence and adverse events compared with tamoxifen (T). Ann Oncol 17(suppl 9): ix94 (Abstract 243PD)
Melisko M, Lin A, Rugo H (2007) Adjuvant therapy for early stage breast cancer (EBC): distant disease-free survival (DDFS) as a predictor for overall survival (OS). J Clin Oncol 25(18S) (Abstract 583)
Rasmussen BB, Regan MM, Lykkesfeldt AE et al (2007) Central assessment of ER, PgR and HER2 in BIG 1-98 evaluating letrozole (L) compared to tamoxifen (T) as initial adjunctive endocrine therapy for postmenopausal women with hormone receptor-positive breast cancer. J Clin Oncol 25(18S) (Abstract 538)
Dowsett M, Cuzick J, Wale C et al (2005) Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 23:7512–7517. doi:10.1200/JCO.2005.01.4829
Dowsett M, Allred DC, on behalf of the transATAC investigators (2006) Relationship between quantitative ER and PgR expression and HER2 status with recurrence in the ATAC trial. Breast Cancer Res Treat 100(suppl 1) (Abstract 48)
Dowsett M, Houghton J, Iden C et al (2006) Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 17:818–826. doi:10.1093/annonc/mdl016
Jakesz R, Jonat W, Gnant M et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366:455–462. doi:10.1016/S0140-6736(05)67059-6
Boccardo F, Rubagotti A, Guglielmini P et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(suppl 7):vii10–vii14. doi:10.1093/annonc/mdl941
Boccardo F, Rubagotti A, Aldrighetti D et al (2007) Switching to an aromatase inhibitor provides mortality benefit in early breast carcinoma: pooled analysis of 2 consecutive trials. Cancer 109:1060–1067. doi:10.1002/cncr.22513
Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092. doi:10.1056/NEJMoa040331
Jonat W, Gnant M, Boccardo F et al (2006) Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 7:991–996. doi:10.1016/S1470-2045(06)70948-2
Buzdar A, Howell A, Cuzick J et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7:633–643. doi:10.1016/S1470-2045(06)70767-7
Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271
Duffy S, on behalf of the ATAC trialists’ group (2006) Anastrozole is associated with a lower risk of endometrial abnormalities than tamoxifen: first report of the ATAC trial endometrial sub-protocol at 6 years’ follow-up. Breast Cancer Res Treat 100(suppl 1) (Abstract 4055)
Kieback DG, Harbeck N, Bauer W et al (2007) Endometrial effects of exemestane compared to tamoxifen within the TEAM trial: results of a prospective, randomized study. J Clin Oncol 25(18S) (Abstract 572)
Crew KD, Apollo A, Greenlee H et al (2006) Prevalence of joint symptoms in postmenopausal women on aromatase inhibitors for early stage breast cancer. Breast Cancer Res Treat 100(suppl 1) (Abstract 5068)
Morales L, Pans S, Westhovens R et al (2006) Importance of synovial fluid retention and thickening in patients with severe musculoskeletal pains treated with letrozole or exemestane: a case series describing the impact of symptoms, clinical findings and magnetic resonance imaging. Breast Cancer Res Treat 100(suppl 1) (Abstract 4056)
Perez EA, Josse RG, Pritchard KI et al (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629–3635. doi:10.1200/JCO.2005.05.4882
Goss PE, Qi S, Cheung AM et al (2004) Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal AI letrozole on bone and lipid metabolism in ovariectomized rats. Clin Cancer Res 10(17):5717–5723. doi:10.1158/1078-0432.CCR-04-0438
McCloskey E, Hannon R, Lakner G et al (2007) The letrozole (L), exemestane (E) and anastrozole (A) pharmacodynamics (LEAP) trial: a direct comparison of bone biochemical measurements between aromatase inhibitors (AIs) in healthy postmenopausal women. J Clin Oncol 25(18S) (Abstract 555)
Brufsky A, Harker WG, Beck JT et al (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829–836. doi:10.1200/JCO.2005.05.3744
Brufsky A, Dong M, Lund K (2006) Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET). Breast Cancer Res Treat 100(suppl 1) (Abstract 5060)
Bundred N, Campbell I, Coleman R et al (2006) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZOFAST study). Eur J Cancer Suppl 4:48 (Abstract 12)
Wasan KM, Goss PE, Pritchard PH et al (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707–715. doi:10.1093/annonc/mdi158
Mouridsen H, Keshaviah A, Coates AS et al (2007) Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. J Clin Oncol 25:5715–5722. doi:10.1200/JCO.2007.12.1665
Herrington DM, Klein KP (2001) Effects of SERMs on important indicators of cardiovascular health: lipoproteins, hemostatic factors, and endothelial function. Womens Health Issues 11:95–102. doi:10.1016/S1049-3867(01)00075-5
Braithwaite RS, Chlebowski RT, Lau J et al (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937–947. doi:10.1046/j.1525-1497.2003.20724.x
McCloskey E, Hannon R, Lakner G et al (2006) Complete data from the letrozole (L), exemestane (E), and anastrozole (A) pharmacodynamic (PD) LEAP trial: direct comparison of safety parameters between aromatase inhibitors (AIs) in healthy postmenopausal women. Breast Cancer Res Treat 100(suppl 1) (Abstract 2092)
Financial disclosure/conflict of interest statement
The author of this article has no commercial associations (e.g., consultancies, stock ownership, equity interests, patentlicensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article. All funding sources supporting the work and all institutional or corporate affiliations of the author are acknowledged.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blackwell, K.L. Are all aromatase inhibitors alike?. Breast Cancer Res Treat 112 (Suppl 1), 35–43 (2008). https://doi.org/10.1007/s10549-008-0233-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-008-0233-9